<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00285207</url>
  </required_header>
  <id_info>
    <org_study_id>TG-001</org_study_id>
    <nct_id>NCT00285207</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Trial of the Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-hydrazone (A-007) Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tigris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tigris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous
      cervical dysplasia (abnormal cell growth). The purpose of this study is to evaluate the
      safety and efficacy of A-007, when used to treat high-grade cervical dysplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study. It will randomize patients in a
      1:1 ratio to topical cervical treatment with A-007, or placebo gel. Following biopsy
      confirmation of High Grade Squamous Intraepithelial Lesions (HSIL), women will treat
      themselves with gel applied to the cervix via an intravaginal applicator. Patients will apply
      gel once daily for 5 consecutive days of a 28-day cycle for 2 cycles. Women will return to
      clinic for safety assessments, colposcopy, cytology, and virologic and immunologic testing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Response</measure>
    <time_frame>baseline and 4 months</time_frame>
    <description>Pathological resonse is defined as a patient who regressed from Cervical intraepithelial neoplasia (CIN) 2/3 to normal at the end of 4 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Tolerability and Systemic Safety of A-007 Will be Assessed by Way of CTCAE 3.0.</measure>
    <time_frame>over the course of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication of Human Papilloma Virus (HPV) Will be Assessed by Way of Cervical Cytology and Swab Collection.</measure>
    <time_frame>over the course of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic Parameters B/T Cells Will be Assessed by B/T Cell Profile Collection.</measure>
    <time_frame>over the course of the trial</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <condition>Uterine Cervical Dysplasia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered topically to the cervix via intravaginal applicator for 5 consecutive days of a 28-day cycle for 2 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25% A007 administered topically to the cervix via intravaginal applicator for 5 consecutive days of a 28-day cycle for 2 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>5 days of 28 day cycle for 2 cycles</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A007</intervention_name>
    <description>5 days of 28 day cycle</description>
    <arm_group_label>A007</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients may be enrolled in the study only if they meet all of the following criteria:

          -  18 years of age or older

          -  The patient or her authorized representative must sign and date an Ethical Review
             Board-approved informed consent document. All aspects of the protocol must be
             explained and written informed consent obtained.

          -  Patients must have histological proof of HSIL (CIN 2/3) disease documented.

          -  Cervical swabs must test positive for HPV (by Hybrid Capture 2).

          -  Patients must have a Hb ≥ 9 g/dl, a peripheral WBC ≥ 3000 mm3 and platelet counts ≥
             100,000 mm3.

          -  Normal hepatic and renal functions - AST and ALT &lt; 2.5 x ULN and creatinine &lt; 1.5 x
             ULN, respectively.

          -  Females of childbearing potential must use one of the following birth control methods
             during the treatment period and 2 weeks thereafter: oral, implantable, injectable
             contraceptives; abstinence (celibacy). Contraceptive sponges, IUD, spermicides,
             sponges, condoms, or partner's vasectomy are not acceptable methods of birth control.

        Exclusion Criteria:

        Patients will be excluded from the study for any of the following preexisting reasons:

          -  Patients with LSIL (CIN 1) or invasive squamous cell carcinoma (SCC).

          -  SIL (CIN) involving the endocervix as determined by endocervical curettage, or
             otherwise not amenable to adequate colposcopic follow-up evaluations, i.e.
             unsatisfactory colposcopy.

          -  CIN 3 involving more than two cervical quadrants on colposcopy.

          -  Patients treated for cervical SIL within the past year.

          -  Patients with other malignancy (except for non-melanoma skin) within the past 5 years.

          -  Patients with any active infections (including HIV) other than HPV.

          -  Patients with known clinically relevant immunological deficiency.

          -  Concurrent treatment with cytotoxic, radiation, or immuno-stimulative therapy, or with
             systemic corticosteroids at a dose of &gt; 5 mg/d of prednisone (or its equivalent).

          -  Participation in another investigational medication trial concurrently or within 30
             days, or prior participation in an HPV vaccine trial. Treatment within the last 30
             days with a medication that has not received regulatory approval at the time of study
             entry.

          -  Concomitant use of topical vaginal medications.

          -  Significant acute or chronic medical or psychiatric illness that, in the judgment of
             the Investigator, could compromise subject safety, limit the subject's ability to
             complete the study, and/or compromise the objectives of the study.

          -  History of allergy or hypersensitivity to cosmetics, toiletries, or other topical or
             dermatologic products.

          -  Pregnant or lactating females who are nursing and will not consent to cease nursing.

          -  Investigators, site personnel directly affiliated with this study, and their immediate
             families. Immediate family is defined as a spouse, parent, child or sibling, whether
             biological or legally adopted.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Burigo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OB/GYN Specialists of the Palm Beaches</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramon Cestero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arrowhead Regional Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul M Fine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Planned Parenthood of Houston &amp; Southeast Texas, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keith A Aqua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Visions Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven C Blank, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Vernon Clinical Research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas G Young, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern California Research Corp</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allan T Sawyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hope Research Institute, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark H Einstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center-Weiler Division</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert M Spitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coastal Connecticut Research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas A deHoop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Greater Cincinnati OB/GYN, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lance R Bruck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jacobi Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Warner K Huh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama Highlands, Dept. of OB/GYN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Del Priore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Presbyterian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael A Gold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma Health Sciences Center Dept of OB/GYN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard S Guido, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Magee-Womens Hospital, Dept of OB/GYN &amp; Reproductive Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip E Young, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IGO Medical Group of San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daron G. Ferris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cynthia J Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Visions Clinical Research-Tucson</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Eduardo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hill Country OB/GYN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phyllis Gee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OB/GYN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Pfeffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robin Black OGNP, Costa Mesa California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan A Cosin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Hospital Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James A Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Carolina Oncology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent A Culotta, Jr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Jefferson OB/GYN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Michael Swor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physician Care Clinical Research, LLC.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Garn R Mabey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Office of R. Garn Mabey, MD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Martino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lehigh Valley Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Global OB/GYN Centers of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William J Mann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jersey Shore University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Highlands, Dept. of OB/GYN</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Research Institute, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research-Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Research Corp</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arrowhead Regional Medical Center</name>
      <address>
        <city>Colton</city>
        <state>California</state>
        <zip>92324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robin Black OGNP</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92629</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IGO Medical Group of San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Connecticut Research, LLC</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global OB/GYN Centers of Florida</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Care Clinical Research, LLC.</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OB/GYN Specialists of the Palm Beaches</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Clinical Research, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Jefferson OB/GYN</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of R. Garn Mabey, MD</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jersey Shore University Medical Center</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center-Weiler Division Dept of OB/GYN &amp; Women's Health</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Downtown Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Cincinnati OB/GYN, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center Dept of OB/GYN</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee-Womens Hospital, Dept of OB/GYN &amp; Reproductive Services</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hill Country OB/GYN</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78737</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of Houston &amp; Southeast Texas, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4601 Old Shepard Place; Bldg 2, Suite 201</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
  </removed_countries>
  <reference>
    <citation>Morgan LR, Thangaraj K, LeBlanc B, Rodgers A, Wolford LT, Hooper CL, Fan D, Jursic BS. Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. J Med Chem. 2003 Oct 9;46(21):4552-63.</citation>
    <PMID>14521417</PMID>
  </reference>
  <reference>
    <citation>Morgan, LR, Hooper, CL, Rodgers, AH, LoRusso, P, Eilender, DE and Culotta, VA. 4,4'-Dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone (A-007): A CD4+ T-Lymphocyte Modulator Useful in the Treatment of Advanced Cancer. Chemotherapy - accepted 2005.</citation>
  </reference>
  <reference>
    <citation>Morgan, LR, Hooper, CL, Rodgers, AH Culotta, V et al. 4,4'-Dihydroxy benzophenone -2,4-dinitrophenylhydrazone (A-007) A Modulator of CD45+ T Lymphocytes in HPV Infected Anogenital Epithelium. In: HPV Vaccines and Immune Therapy, Cambridge, United Kingdom, 2003</citation>
  </reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2006</study_first_submitted>
  <study_first_submitted_qc>January 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2006</study_first_posted>
  <results_first_submitted>August 30, 2010</results_first_submitted>
  <results_first_submitted_qc>September 23, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 11, 2010</results_first_posted>
  <last_update_submitted>September 23, 2010</last_update_submitted>
  <last_update_submitted_qc>September 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Tigris</organization>
  </responsible_party>
  <keyword>Cervical Intraepithelial Neoplasia (CIN)</keyword>
  <keyword>High-grade Cervical Intraepithelial Neoplasia</keyword>
  <keyword>High-grade Squamous Intraepithelial Lesions (HSIL)</keyword>
  <keyword>Human Papilloma Virus (HPV)</keyword>
  <keyword>High-Grade Cervical Intraepithelial Lesions (CIN 2/3)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo (no treatment)</description>
        </group>
        <group group_id="P2">
          <title>A007</title>
          <description>Experimental A007</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo (no treatment)</description>
        </group>
        <group group_id="B2">
          <title>A007</title>
          <description>Experimental A007</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="147"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="6"/>
                    <measurement group_id="B2" value="28.7" spread="7.9"/>
                    <measurement group_id="B3" value="28.4" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathological Response</title>
        <description>Pathological resonse is defined as a patient who regressed from Cervical intraepithelial neoplasia (CIN) 2/3 to normal at the end of 4 months.</description>
        <time_frame>baseline and 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (no treatment)</description>
          </group>
          <group group_id="O2">
            <title>A007</title>
            <description>Experimental A007</description>
          </group>
        </group_list>
        <measure>
          <title>Pathological Response</title>
          <description>Pathological resonse is defined as a patient who regressed from Cervical intraepithelial neoplasia (CIN) 2/3 to normal at the end of 4 months.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Tolerability and Systemic Safety of A-007 Will be Assessed by Way of CTCAE 3.0.</title>
        <time_frame>over the course of the trial</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eradication of Human Papilloma Virus (HPV) Will be Assessed by Way of Cervical Cytology and Swab Collection.</title>
        <time_frame>over the course of the trial</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunologic Parameters B/T Cells Will be Assessed by B/T Cell Profile Collection.</title>
        <time_frame>over the course of the trial</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo (no treatment)</description>
        </group>
        <group group_id="E2">
          <title>A007</title>
          <description>Experimental A007</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>TigrisPharmaceuticals</organization>
      <email>info@tigrispharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

